Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic...

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Pharmacology

Background:

• HDL-increasing drugs like fenofibrate and niacin have not reduced cardiovascular risk in type 2 diabetes patients.
• Potential reasons for treatment failure include drug-induced quantitative and qualitative modifications of HDL particles.

Purpose of the Study:

• To investigate the quantitative and qualitative effects of niacin/laropiprant (ERN/LPR) and fenofibrate (FFB) on HDL in type 2 diabetes patients.
• To compare the impact of these HDL-modifying agents on HDL cholesterol, particle characteristics, and associated enzyme activities.

Main Methods:

• A prospective, randomized, crossover trial involving 30 type 2 diabetes patients with low HDL, treated with simvastatin plus either ERN/LPR or FFB for 12 weeks.
• HDL metabolomics, biochemical determinations, and physical examinations were performed at baseline and after each intervention.
• A control group of 30 non-diabetic individuals with normal HDL was included for baseline comparison.

Main Results:

• ERN/LPR significantly increased HDL cholesterol and apoA-I, while FFB increased apoA-II and Preβ1-HDL.
• Neither drug normalized HDL particle size or number; both decreased CETP, LCAT, and PAF-AH activities to varying degrees.
• No significant antioxidant improvements were observed with either treatment despite differing effects on antioxidant parameters.

Conclusions:

• ERN/LPR and FFB exert distinct effects on HDL quantity, quality, and cholesterol levels in type 2 diabetes.
• The differential actions of these HDL-modifying drugs on HDL characteristics should be considered during clinical prescription.
• Further research is needed to understand how these qualitative HDL changes influence cardiovascular outcomes in diabetic patients.